Therefore, developing therapeutic strategies that precisely modulate the AMPK signaling pathway through a deeper understanding of AMPK regulatory mechanisms holds significant importance for expanding treatment options for MASLD. The gene discussed is PRKAA1; the disease is metabolic dysfunction-associated steatotic liver disease.